Affiliation: Duke University Medical Center
- New combination treatments in the management of diabetes: focus on sitagliptin-metforminJennifer Green
Duke University Medical Center, Department of Medicine, Division of Endocrinology, Durham, North Carolina 27710, USA
Vasc Health Risk Manag 4:743-51. 2008..Animal studies also suggest that dipeptidyl peptidase-4 inhibitor treatment may help to preserve beta cell mass; however, it is unclear at present whether or not this will prove to be the case in humans...
- understanding the type 2 diabetes mellitus and cardiovascular disease risk paradoxJennifer B Green
Associate Professor of Medicine, Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Duke Clinical Research Institute, Durham, NC
Postgrad Med 126:190-204. 2014..Interventions that focus on the management of CV risk factors and glucose lowering with medications that are not cardiotoxic represent an optimal and attainable treatment approach. ..
- Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacyMary Elizabeth Cox
Department of Medicine, Division of Endocrinology, Metabolism, and Nutrition Duke University Medical Center, Durham, NC, USA
Drug Healthc Patient Saf 2:7-19. 2010..This review summarizes the available data on the efficacy, safety, and tolerability of these medications...
- The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safetyJennifer B Green
Division of Endocrinology, Duke University Medical Center, Durham, NC 27705, USA
Postgrad Med 124:54-61. 2012..Long-term cardiovascular safety trials are currently underway to more fully define and understand the cardiovascular impact of DPP-4 therapy in patients with type 2 diabetes mellitus...
- Are sulfonylureas passé?Jennifer B Green
Duke University Medical Center, Division of Endocrinology, DUMC Box 3222, Baker House, Room 280, Durham, NC 27710, USA
Curr Diab Rep 6:373-7. 2006..Fortunately, newer agents such as glimepiride appear less likely to adversely affect the myocardium. These agents can often be used successfully as one component of combination therapy for diabetes management...
- Exenatide and rimonabant: new treatments that may be useful in the management of diabetes and obesityJennifer B Green
Division of Endocrinology, Metabolism, and Nutrition, Duke University Medical Center, Baker House Room 280, Durham, NC 27710, USA
Curr Diab Rep 7:369-75. 2007..These medications may well prove to be attractive alternatives or additions to our more established diabetes therapies; however, these drugs have a side-effect profile that may limit their applicability to certain populations...